Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

摘要

IntroductionMany patients with chronic obstructive pulmonary disease (COPD) prescribed long-acting muscarinic antagonist (LAMA) monotherapy remain symptomatic. This multivariable analysis of a previously reported claims-linked, cross-sectional survey assessed symptom burden measured by the COPD assessment test (CAT) in patients treated with LAMA monotherapy. MethodsEligible patients aged?≥?40?years with COPD (≥?2 International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] diagnosis codes?≥?30?days apart during the 12-month baseline period) and?≥?2 claims for LAMA monotherapy in the latter half of the baseline period were identified using claims data from the Optum Research Database. Patients completed a survey and 7-day daily diary; baseline clinical characteristics and resource utilization were assessed from claims data. Association between symptom burden and baseline characteristics was assessed using generalized linear regression modeling with normal distribution and identity link. ResultsOverall, 433 patients prescribed LAMA monotherapy with claims-linked survey and diary data were included in the analysis. Most patients (85.5%) had a mean CAT score?≥?10; 39.0% had scores?≥?21. Overall, the factors most related to a clinically meaningful increase in CAT score (≥?2 points) were being diagnosed with COPD for??5?years and being a current smoker (2.25 points, P =?0.003 and 2.22 points, P =?0.025, respectively). ConclusionsResults demonstrate that many patients with COPD receiving LAMA monotherapy remain symptomatic, especially those diagnosed??5?years ago or those who continue to smoke. Use of patient-reported outcomes such as the CAT should be considered part of routine visits for patients with COPD. FundingGlaxoSmithKline (GSK study number 205862 [HO-16-16642]).